A Global, Multicenter, Observational Study Evaluating the Impact of rFVIIIFc and rFIXFc on Patient-reported Treatment Burden and Health Economic Outcomes

Trial Profile

A Global, Multicenter, Observational Study Evaluating the Impact of rFVIIIFc and rFIXFc on Patient-reported Treatment Burden and Health Economic Outcomes

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Efmoroctocog alfa (Primary) ; Eftrenonacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Therapeutic Use
  • Acronyms FORWARD
  • Sponsors Biogen
  • Most Recent Events

    • 15 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 31 Jul 2015 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020 as per ClinicalTrials.gov record.
    • 31 Jul 2015 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2020 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top